Registration Links (4 Options)
Speakers Reg Patient Reg Reg for Clinical Trials Community Network
Logo

Bone Marrow & Stem Cell Transplantation

Clinical indications for autologous and allogeneic hematopoietic cell transplantation, conditioning regimens, and graft-versus-host disease management.

Overview

Hematopoietic Stem Cell Transplantation (HSCT), commonly referred to as Bone Marrow Transplantation (BMT), is a specialized cellular therapy that replaces diseased, malignant, or ablated bone marrow with healthy hematopoietic progenitor stem cells. It serves as a curative modality for high-risk hematological malignancies, severe aplastic anemia, hemoglobinopathies, and inherited immune deficiencies.

Autologous vs. Allogeneic Transplantation

Parameter Autologous Transplantation Allogeneic Transplantation
Stem Cell Origin Patient's own harvested and cryopreserved stem cells HLA-matched sibling, matched unrelated donor (MUD), haploidentical donor, or cord blood
Primary Therapeutic Mechanism Hematopoietic rescue allowing high-dose myeloablative chemotherapy Graft-versus-Tumor (GvT / GvL) immunological eradication by donor T-cells
Primary Malignancies Treated Multiple Myeloma, Relapsed Hodgkin & Non-Hodgkin Lymphoma, Neuroblastoma Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Aplastic Anemia
GvHD Risk Zero risk of Graft-versus-Host Disease Requires post-transplant immunosuppression (Tacrolimus, Methotrexate, Cyclophosphamide) to prevent GvHD

5-Phase Clinical Transplantation Pathway

  1. Donor Matching & Pre-Transplant Evaluation: High-resolution HLA typing (HLA-A, -B, -C, -DRB1, -DQB1), organ function testing, and infectious disease screening.
  2. Stem Cell Harvest & Cryopreservation: G-CSF mobilization and leukapheresis collecting CD34+ hematopoietic stem cells.
  3. Conditioning Regimen: Administration of myeloablative or reduced-intensity conditioning (RIC) chemotherapy (Busulfan, Fludarabine, Melphalan) with or without Total Body Irradiation (TBI).
  4. Cell Infusion (Day 0): Intravenous infusion of donor stem cells via central venous catheter.
  5. Engraftment & Immune Reconstitution: Recovery of absolute neutrophil count (ANC > 500/μL) and platelets (> 20,000/μL) typically occurring between Day 14 and Day 28 post-infusion.

Complications & Supportive Care

  • Graft-versus-Host Disease (GvHD): Acute (skin rash, hyperbilirubinemia, diarrhea) or chronic (fibrosis, sicca syndrome) donor immune activation against recipient tissues.
  • Neutropenic Infection Prophylaxis: HEPA-filtered positive pressure rooms, antibacterial, antifungal (Posaconazole), and antiviral (Acyclovir) coverage.
  • Sinusoidal Obstruction Syndrome (SOS / VOD): Hepatic veno-occlusive injury monitored and managed with Defibrotide.
Allogeneic and autologous stem cell transplants are coordinated by specialized cellular therapy teams in FACT-accredited transplant centers with long-term survivorship follow-up.